HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- (1,4- benzodioxan- 6- ylcarbonyl)piperidine

structure in first source

Also Known As:

CX-546; CX546

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine: 7
  - Dioxoles
    - 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine: 7

Experts

1.	Wang, Jing: 3 articles (01/2021 - 11/2014)
2.	Lee, Michelle: 2 articles (11/2016 - 11/2014)
3.	Su, Chen: 2 articles (11/2016 - 11/2014)
4.	Cha, Shuhan: 1 article (01/2022)
5.	Guo, Guoqing: 1 article (01/2022)
6.	Li, Jiong: 1 article (01/2022)
7.	Meng, Lianghui: 1 article (01/2022)
8.	Wu, Fengming: 1 article (01/2022)
9.	Zhang, Huijie: 1 article (01/2022)
10.	Zhang, Jifeng: 1 article (01/2022)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 05/17/2023 - "Ampakines (CX546 and CX1739) but not riluzole altered the antitumor efficacy of cisplatin in two human ovarian cancer cell lines, OVCAR8 and SKOV3.ip1, in vitro. "
2.	Pain (Aches) 11/01/2016 - "Meanwhile, CX546 delivered locally into the NAc provided pain-relieving effects in both PI (50% withdrawal threshold of 6.81 ± 1.91 vs. 0.50 ± 0.03 g; control, n = 6; CX546, n = 8) and persistent postoperative pain (spared nerve injury) models (50% withdrawal threshold of 3.85 ± 1.23 vs. 0.45 ± 0.00 g; control, n = 7; CX546, n = 11). " 11/01/2016 - "Systemic administration of CX546 (n = 13), compared with control (n = 13), reduced mechanical hypersensitivity (50% withdrawal threshold of 6.05 ± 1.30 g [mean ± SEM] vs. 0.62 ± 0.13 g), and it reduced depressive features of pain by decreasing immobility on the forced swim test in PI-treated rats (89.0 ± 15.5 vs. 156.7 ± 18.5 s). " 11/01/2014 - "They found that CX546, compared with control, also reduced depressive symptoms of pain by decreasing immobility on the forced swim test in both SNI (both DMSO and CX546 groups, n = 8) and CFA models (both DMSO and CX546 groups, n = 10). " 11/01/2014 - "The authors studied AMPAkines (CX546 and CX516) in rat spared nerve injury (SNI) model of neuropathic pain and Complete Freund's Adjuvant (CFA) model of inflammatory pain. "
3.	Chronic Pain 01/01/2021 - "Meanwhile, CX546, a well-known AMPAkine, restored the anti-nociceptive response of PL-PFC neurons in the chronic pain condition. " 01/01/2021 - "In addition, both systemic administration and direct delivery of CX546 into the PL-PFC inhibited symptoms of chronic pain, whereas optogenetic inactivation of the PFC neurons or administration of AMPA receptor antagonists in the PL-PFC blocked the anti-nociceptive effects of CX546. "
4.	Disease Progression 01/01/2021 - "In vivo, short and early administration of CX546 to Mecp2 null mice prolongs lifespan, delays the disease progression, and rescues motor abilities and spatial memory, thus confirming the value for RTT of an early restoration of neuronal activity."
5.	Respiratory Insufficiency (Respiratory Failure) 12/15/2006 - "We determined whether the ampakine CX546 would enhance respiratory drive and rhythmogenesis across various stages of development and whether this ampakine could counter opioid- and barbiturate-induced respiratory depression. " 12/15/2006 - "CX546 effectively reverses opioid- and barbiturate-induced respiratory depression without reversing the analgesic response. "

Related Drugs and Biologics

1.	Riluzole
2.	Cisplatin (Platino)
3.	Analgesics (Analgesic Drugs)
4.	AMPA Receptors (AMPA Receptor)
5.	N-Methylaspartate (NMDA)
6.	Freund's Adjuvant
7.	Dimethyl Sulfoxide (DMSO)
8.	Opioid Analgesics (Opioids)
9.	1-(quinoxalin-6-ylcarbonyl)piperidine (CX516)
10.	barbituric acid (barbiturate)

Related Therapies and Procedures

1.	Intraperitoneal Injections